Robeco Institutional Asset Management B.V. increased its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 21.8% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 129,743 shares of the biotechnology company’s stock after buying an additional 23,239 shares during the period. Robeco Institutional Asset Management B.V. owned about 0.30% of United Therapeutics Corporation worth $16,832,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in UTHR. Capstone Asset Management Co. raised its stake in United Therapeutics Corporation by 5.8% in the first quarter. Capstone Asset Management Co. now owns 5,723 shares of the biotechnology company’s stock valued at $775,000 after buying an additional 316 shares in the last quarter. Nationwide Fund Advisors raised its stake in United Therapeutics Corporation by 5.6% in the first quarter. Nationwide Fund Advisors now owns 109,868 shares of the biotechnology company’s stock valued at $14,874,000 after buying an additional 5,789 shares in the last quarter. DUPONT CAPITAL MANAGEMENT Corp raised its stake in United Therapeutics Corporation by 10.2% in the first quarter. DUPONT CAPITAL MANAGEMENT Corp now owns 18,800 shares of the biotechnology company’s stock valued at $2,545,000 after buying an additional 1,737 shares in the last quarter. Oregon Public Employees Retirement Fund raised its stake in United Therapeutics Corporation by 15.4% in the first quarter. Oregon Public Employees Retirement Fund now owns 29,202 shares of the biotechnology company’s stock valued at $3,953,000 after buying an additional 3,904 shares in the last quarter. Finally, Canada Pension Plan Investment Board raised its stake in United Therapeutics Corporation by 123.8% in the first quarter. Canada Pension Plan Investment Board now owns 55,502 shares of the biotechnology company’s stock valued at $7,514,000 after buying an additional 30,700 shares in the last quarter.

Shares of United Therapeutics Corporation (NASDAQ UTHR) opened at 129.61 on Tuesday. The stock has a market capitalization of $5.63 billion, a P/E ratio of 15.03 and a beta of 1.51. United Therapeutics Corporation has a 52-week low of $110.90 and a 52-week high of $169.89. The company has a 50 day moving average price of $130.18 and a 200-day moving average price of $133.12.

United Therapeutics Corporation (NASDAQ:UTHR) last announced its earnings results on Thursday, July 27th. The biotechnology company reported ($1.25) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $3.61 by $4.86. United Therapeutics Corporation had a return on equity of 20.96% and a net margin of 24.18%. The firm had revenue of $444.60 million for the quarter, compared to analyst estimates of $391.53 million. During the same quarter last year, the business posted $4.42 EPS. The firm’s revenue was up 7.8% compared to the same quarter last year. On average, analysts predict that United Therapeutics Corporation will post $10.09 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Robeco Institutional Asset Management B.V. Buys 23,239 Shares of United Therapeutics Corporation (UTHR)” was published by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/robeco-institutional-asset-management-b-v-buys-23239-shares-of-united-therapeutics-corporation-uthr/1529445.html.

UTHR has been the subject of several recent research reports. ValuEngine lowered United Therapeutics Corporation from a “strong-buy” rating to a “buy” rating in a report on Friday, June 2nd. Jefferies Group LLC reissued a “sell” rating and set a $105.00 price target on shares of United Therapeutics Corporation in a report on Thursday, June 8th. BidaskClub raised United Therapeutics Corporation from a “strong sell” rating to a “sell” rating in a report on Friday, June 9th. UBS AG reissued a “sell” rating and set a $106.00 price target on shares of United Therapeutics Corporation in a report on Thursday, July 6th. Finally, Zacks Investment Research lowered United Therapeutics Corporation from a “hold” rating to a “sell” rating in a research note on Thursday, July 13th. Six research analysts have rated the stock with a sell rating, six have issued a hold rating and three have assigned a buy rating to the company. United Therapeutics Corporation currently has an average rating of “Hold” and an average price target of $134.50.

In other United Therapeutics Corporation news, CEO Martine A. Rothblatt sold 1,238 shares of the stock in a transaction that occurred on Thursday, August 24th. The shares were sold at an average price of $130.65, for a total transaction of $161,744.70. Following the transaction, the chief executive officer now owns 2,307 shares of the company’s stock, valued at $301,409.55. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Martine A. Rothblatt sold 1,251 shares of the stock in a transaction that occurred on Thursday, June 1st. The stock was sold at an average price of $125.02, for a total transaction of $156,400.02. Following the transaction, the chief executive officer now directly owns 1,391 shares in the company, valued at approximately $173,902.82. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 24,622 shares of company stock worth $3,203,127. 7.80% of the stock is owned by company insiders.

United Therapeutics Corporation Company Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Institutional Ownership by Quarter for United Therapeutics Corporation (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.